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Abstract. Insertion of melatonin for 7 days helped to reduce 1,7 times basal glucose level in the group of animals with overt diabetes. 
Activity of glucose-6-phosphate dehydrogenase, glutathione peroxidase and glutathione reductase in the liver of rats with overt 
diabetes was on 47%, 33%, and 35% respectively lower than in control rats that were under artificial equinox. In rat liver with overt 
and latent diabetes occurred reduction of reduced glutathione content on 25% and 41% respectively compared with those of control. 
Insertion of melatonin to diabetic rats helped in normalization of parameters. 
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Introduction. Melatonin is a lipophilic hormone 
produced by the Pineal gland during the night [3, 15]. It 
may act as a paracrine, intracrine and autocrine agent 
expressing an overall homeostatic function and 
pleiotropic effect. It is responsible for carrying out the 
following functions by controlling other hormones:         
1) regulation of circadian sleep-wake cycle; 2) controls 
sex drive and reproduction by inhibiting release of GnTH 
(Gonadotrophic Hormone); 3) controls body weight and 
energy balance; 4) controls appetite; 5) controls metabolic 
function; 6) controls balance; 7) controls muscular 
coordination; 8) controls immune system when it is 
affected by bacterial and viral diseases, affected by 
chemical pollutants and in the presence of excessive 
radical activity; 9) antioxidant effects; 10) may reduce 
damage caused by types of Parkinson’s disease;            
11) prevent cardiac arrhythmia; 12) increase longevity; 
13) prevents damage to DNA by some carcinogens. 
Melatonin production is inhibited when there is an 
increase in the light received by the retina while 
production is stimulated when there is a decrease in the 
light received by the retina (darkness stimulates 
production) [16]. Hence, during evenings, as the light 
received by the retina reduces melatonin production sets 
in, this evening onset is called the dim-light melatonin 
onset (DLMO). Exposure to light inhibits the enzyme    
N-acetyltransferase, the enzyme which converts Serotonin 
to Melatonin, hence reducing melatonin production. 
Being exposed to bright lights in the evening or too little 
light during the day can disrupt the body' s normal 
melatonin cycles. For example, jet lag, shift work, and 
poor vision can disrupt melatonin cycles [4]. Most 
functions of melatonin are produced through activation of 
melatonin receptors, while other functions are carried out 
due to its pervasive and powerful antioxidant, with a 
particular role in protection of nuclear and mitochondrial 
DNA [5]. 
Alloxan and streptozotocin are toxic glucose analogues 
that preferentially accumulate in pancreatic beta cells via 
the GLUT2 glucose transporter. In the presence of 
intracellular thiols, especially glutathione, alloxan 
generates reactive oxygen species (ROS) in a cyclic redox 
reaction with its reduction product, dialuric acid. 
Autoxidation of dialuric acid generates superoxide 
radicals, hydrogen peroxide and, in a final iron-catalysed 
reaction step, hydroxyl radicals. These hydroxyl radicals 
are ultimately responsible for the death of the beta cells, 
which have a particularly low antioxidative defence 
capacity, and the ensuing state of insulin-dependent 
'alloxan diabetes'. As a thiol reagent, alloxan also 
selectively inhibits glucose-induced insulin secretion 
through its ability to inhibit the beta cell glucose sensor 
glucokinase. Following its uptake into the beta cells, 
streptozotocin is split into its glucose and methylnitro-
sourea moiety. Owing to its alkylating properties, the 
latter modifies biological macromolecules, fragments 
DNA and destroys the beta cells, causing a state of 
insulin-dependent diabetes. The targeting of mitochond-
rial DNA, thereby impairing the signalling function of 
beta cell mitochondrial metabolism, also explains how 
streptozotocin is able to inhibit glucose-induced insulin 
secretion [11]. 
Melatonin influences insulin secretion both in vivo and 
in vitro. (i) The effects are MT(1)-and MT(2)-receptor-
mediated. (ii) They are specific, high-affinity, pertussis-
toxin-sensitive, G(i)-protein-coupled, leading to inhibition 
of the cAMP-pathway and decrease of insulin release. 
Furthermore, melatonin inhibits the cGMP-pathway, 
possibly mediated by MT(2) receptors. In this way, 
melatonin likely inhibits insulin release. A third system, 
the IP(3)-pathway, is mediated by G(q)-proteins, 
phospholipase C and IP(3), which mobilize Ca(2+) from 
intracellular stores, with a resultant increase in insulin. 
(iii) Insulin secretion in vivo, as well as from isolated 
islets, exhibits a circadian rhythm. This rhythm, which is 
apparently generated within the islets, is influenced by 
melatonin, which induces a phase shift in insulin 
secretion. (iv) Observation of the circadian expression of 
clock genes in the pancreas could possibly be an 
indication of the generation of circadian rhythms in the 
pancreatic islets themselves. (v) Melatonin influences 
diabetes and associated metabolic disturbances. The 
diabetogens, alloxan and streptozotocin, lead to selective 
destruction of beta-cells through their accumulation in 
these cells, where they induce the generation of ROS. 
Beta-cells are very susceptible to oxidative stress because 
they possess only low-antioxidative capacity. Results 
suggest that melatonin in pharmacological doses provides 
protection against ROS. (vi) Finally, melatonin levels in 
plasma, as well as the arylalkylamine-N-acetyltransferase 
(AANAT) activity, are lower in diabetic than in 
nondiabetic rats and humans. In contrast, in the pineal 
gland, the AANAT mRNA is increased and the insulin 
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receptor mRNA is decreased, which indicates a close 
interrelationship between insulin and melatonin. 
It acts as an antioxidant, neutralizing harmful oxidative 
radicals, and it is capable of activating certain antioxidant 
enzymes [3]. It is a powerful antioxidant that easily 
crosses the cell membranes and blood-brain barrier [10, 
17]. It acts as a direct scavenger of OH∙, O2, and NO. 
Oxidative stress plays a pivotal role in the development 
of diabetes complications, both microvascular and cardio-
vascular [1]. The increase in glycoxidation and lipoxi-
dation products in plasma and tissue proteins suggests 
that oxidative stress is increased in diabetes [6, 9]. 
Exogenous melatonin normalizes impaired due alloxan 
diabetes and tetrachlormethane hepatitis glucose-6-
phosphatase activity in rat liver [19]. 
It has been ascertained that an alloxan monohydrate 
administration to rats results in a significant elevation of 
the level of basal glycemia in the blood, and an increase 
of the activities of lactate dehydrogenase and glucose-6-
phosphatase in the liver, however a decrease of the 
glycogen content and the activity glucose-6-phosphate 
dehydrogenase was in a direct dependence on the 
presence of hyperglycemia. The established changes of 
the indices of the carbohydrate metabolism in animals 
with alloxan diabetes turned out to be more marked under 
the conditions of permanent lighting than with equinox or 
permanent darkness. With a 7-day introduction of a 
higher dose of melatonin an improvement of the state of 
carbohydrate metabolism was marked and that was 
accompanied with a normalization of the indices under 
study, apart from the activities of glucose-6-phosphatase 
in the liver which is normalized in case of a 42-day 
administration that was also characterized by a 
normalization of the level of glycosylated hemoglobin in 
the rats blood [18]. 
The aim was to determine the influence of melatonin 
on basal levels of glucose, reduced glutathione (GSH), 
activity of glucose-6-phosphate dehydrogenase (G6PD), 
glutathione peroxidase (GPx) and glutathione reductase 
(GR) in the liver of alloxan diabetic rats under conditions 
of constant light. 
Material and methods. The experiments were carried 
out on 60 sexually mature male albino, not thoroughbred 
rats with the body mass – 0,18-0,20 kg. Alloxan diabetes 
was evoked via injecting the rats with a 5% solution of 
alloxan monohydrate intraperitoneally in a dose of 170 
mg/kg following a 24 hour period of fasting [11]. The 
melatonin preparation was used in the research (the 
manufacturer – “Sigma”, USA). The animals were 
divided into 6 subgroups: 1) rats (the control group) that 
were under artificial equinox (Light:Darkness=12:12);    
2) rats that where under conditions of constant light    
(L:D=24:0); 3) alloxan diabetic rats (L:D=24:0);             
4) alloxan diabetic animals which were introduced the 
melatonin preparation intraperitoneally in a dose of 10 
mg/kg at 8 a. m. daily during 7 days starting with a 5-th 
24 hour period after the injection of alloxan (L:D=24:0); 
5) alloxan diabetic rats with latent (basal glycemia < 6,9 
mmol/l) diabetes (L:D=24:0); 6) rats with latent diabetes 
which were introduced the melatonin preparation 
intraperitoneally in a dose of 10 mg/kg at 8 a. m. daily 
during 7 days starting with a 5-th 24 hour period after the 
injection of alloxan (L:D=24:0). Blood was taken from 
the tail vein evaluate the BG level with the use of One 
Touch Ultra (LifeScan, USA). On the third day the death 
of a part (50%) of the alloxan diabetic animals was 
observed. Rats were sacrificed at the twelfth day of the 
experiment accordance with the ethical treatment of 
animals. Liver tissue immediately after decapitation took 
the cold and refrigerated prepared homogenates in 50 mM 
Tris-HCl buffer (pH=7.4). Determinations of GSH, 
activity G6PD, GPx and GR were by standard methods 
[8]. Statistical analysis of results was conducted by 
Student’s test. Sufficient level considered probability 
differences r≤0,05. 
 Results. Staying animals in lighting conditions (figure 1) 
around the clock throughout the week was accompanied by a 
tendency to increase in basal blood glucose by 10% from 
baseline this indicator on the 4 th day of the experiment. 
Insertion of melatonin for 7 days helped to reduce (but not 
normalization as in the previous series of experiments under 
conditions of constant darkness and equinox) [7, 18] 1,7 
times compared with the baseline, basal glucose level in 
the group of animals with overt diabetes, indicating its 
hypoglycemic action but less pronounced. 
The prevalence of diabetes has exponentially increased 
in recent decades due to environmental factors such as 
nocturnal lifestyle and aging, both of which influence the 
amount of melatonin produced in the pineal gland. [14]. 
Activity (table 1)  of G6PD, GPx and GR in the liver of 
rats with overt diabetes was on 47%, 33%, and 35% 
respectively lower than in control rats that were under 
artificial equinox.  
Probable reduction of melatonin synthesis and 
secretion under conditions of constant illumination 
coupled with reduced sensitivity to insulin, reduces the 
activity (table 1) of G6PD in control rats and rats with 
diabetes. Under these conditions there was no typical 
increase in activity of G6PD in the group of animals with 
latent diabetes [18], but rather there was a decline of this 
indicator compared with those of control rats, provided 
equinox.  
In the liver of rats with latent diabetes activities of 
G6PD, GPx and GR were on 22%, 15% and 20% 
respectively lower than in control animals. In rat liver 
with overt and latent diabetes occurred reduction of G-SH 
on 25% and 41% respectively compared with those of 
control. We know [3] that pinealectomy, same as its 
hypofunction caused by permanent lighting, leading to 
decreased synthesis and secretion of melatonin, which 
causes insulin resistance and reduce the gene expression 
of glucose transporter GLUT 4, 2, 1. It is logical that the 
activity of G6PD is reduced under conditions of constant 
illumination during diabetes mellitus, whether an 
administration of melatonin leads to increased its activity. 
Under the influence of melatonin increase (on 20% 
than in control) activity of G6PD in the liver of rats may 
be due to the increasing number of substrate for G6PD 
(stimulating the flow of glucose into cells and its 
phosphorylation) and direct action [14]. 
Insertion of melatonin to diabetic rats helped in 
normalization of parameters that we studied. According to 
our investigations the introduction of melatonin 
intraperitoneally in a dose of 10 mg/kg at 8 a. m. daily 
during 7 days to alloxan diabetic rats under
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Fig. 1. The level of basal glycemia (mmol/l) in blood of rats, (n=6, x±Sx): 1. a, b, c - changes are reliable  (р≤0,05).              
2. a - concerning intact rats ; b - concerning rats with overt diabetes; c – concerning rats with latent diabetes; d – concerning 
indices on 4-th day.  
 
Table 1. Influence of melatonin on the indices of glutathione system in the liver of alloxan diabetic rats (x±Sx, n=6) 
      Indexes  
 
Indexes 
Glucose-6-phosphate 
dehydrogenase, nmol / 
min×mg 
Glutathione 
reductase, nmol / 
min×mg 
 
G-SH, mkmol/g 
tissue  
 
Glutathione 
peroxidase, 
nmol / min×mg 
Control group (L:D=12:12) 6,5±0,18 4,4±0,22 7,0±0,42 155,8±12,4 
Control group (L:D=24:0) 5,8±0,25 a 4,3±0,25 6,9±0,45 152,5±11,1  
Overt diabetes (L:D = 24:0)  3,4±0,46a 2,9±0,27a 4,1±0,30a 104,4±12,0a 
Overt diabetes+ melatonin 
(L:D=24:0) 
6,6±0,55b 4,7±0,32b 6,7±0,41b 150,2±10,3b 
Latent diabetes 
(L:D=24:0) 
5,0±0,52a,b 3,5±0,30a,b 5,3±0,40a,b 132,4±12,1 
Latent diabetes + melatonin 
(L:D=24:0) 
7,7±0,26a,b,c 4,5±0,26b,c 7,1±0,40b,c 160,0±9,0b 
1. a, b, c - changes are reliable  (р≤0,05).  
2. a - concerning intact rats ; 
    b - concerning rats with overt diabetes; 
    c – concerning rats with latent diabetes. 
conditions of  constant light is conducive to a decrease in 
them of the level of fasting glucose, as well as – a 
stabilization of the indices of the body’s antioxidant 
defense (glucose-6-phosphate dehydrogenase, glutathione 
peroxidase, glutathione reductase and reduced glutathione 
in liver) disturbed under the conditions of an absolute 
deficit of insulin.  
An elevated oxidative status in the aging organism may 
be involved in the development of non-insulin dependent 
diabetes mellitus (NIDDM). Melatonin, a potent 
antioxidant agent, is essential for glucose homeostasis and 
regulation. It was determined [13] the influence of 
melatonin supplementation on the oxidative stress 
parameters in elderly NIDDM patients. The malon-
dialdehyde (MDA) concentration, Cu-Zn superoxide 
dismutase (SOD-1) activity in erythrocytes, the level of 
nitrate/nitrite in plasma and morning melatonin 
concentration and oxidase activity of ceruloplasmin (Cp) 
0
2
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14 on 4-th day
on 12-th day
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bb b,c
a,b,
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in serum in 15 elderly NIDDM patients at baseline and 
after the 30 days of melatonin supplementation (5 mg 
daily) in comparison with levels in 15 healthy elderly 
volunteers were determined. A significant increase of 
MDA level and decrease of SOD-1 activity and melatonin 
concentration were observed in NIDDM patients. Cp 
oxidase activity and nitrate/nitrite level were similar in 
both examined groups. Melatonin administration in 
NIDDM patients resulted in a significant increase in the 
morning melatonin concentration and SOD-1 activity, and 
a reduction in the MDA level and Cp oxidase activity. 
Statistically significant alterations in nitrate/nitrite levels 
were not observed. These results indicate an improvement 
of antioxidative defense after melatonin supplementation 
in the NIDDM individuals and suggest melatonin 
                                                                          
supplementation as an additional treatment for the control 
of diabetic complications [13]. 
It was detected, that melatonin stimulates glucose 
transport to skeletal muscle cells via insulin receptor 
substrate-1/phosphoinositide 3-kinase (IRS-1/PI-3-kinase) 
pathway, which implies, at the molecular level, its role in 
glucose homeostasis and possibly in diabetes. 
Additionally, exposure to light at night and aging, both of 
which lower endogenous melatonin levels may contribute 
to the incidence and/or development of diabetes [12, 14].   
Conclusion. Under conditions of permanent light 
exogenous melatonin activates antioxidant glutathione 
dependent enzymes in the liver of alloxan diabetic rats 
that ultimately provides increased content of G-SH  one 
of the main endogenous antioxidant.
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Влияние мелатонина на функционирование глутатионовой системы в печени крыс с аллоксановым диабетом в 
условиях круглосуточного освещения 
И. Н. Яремий, А. Ю. Кушнир, К. А. Харченко 
Аннотация. Введение мелатонина в течение 7 дней способствовало уменьшению в 1,7 раза базального уровня глюкозы в 
группе животных с явным диабетом. Активность глюкозо-6-фосфатдегидрогеназы, глутатионпероксидазы и 
глутатионредуктазы в печени крыс с явным диабетом была на 47%, 33% и 35% соответственно ниже, чем у контрольных 
крыс, которые были при искусственном равноденствия. В печени крыс с явным и скрытым диабетом произошло снижение 
содержания глутатиона восстановленного на 25% и 41% соответственно по сравнению с соответственным контролем. 
Введение мелатонина диабетическим крысам помогло в нормализации показателей. 
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